Modelling and prognostication of growth in the number of patients treated for neovascular age-related macular degeneration.
Aged, 80 and over
Angiogenesis Inhibitors
/ administration & dosage
Denmark
/ epidemiology
Female
Follow-Up Studies
Humans
Incidence
Intravitreal Injections
Male
Models, Theoretical
Prognosis
Ranibizumab
/ administration & dosage
Retrospective Studies
Vascular Endothelial Growth Factor A
/ antagonists & inhibitors
Visual Acuity
Wet Macular Degeneration
/ drug therapy
anti-VEGF therapy
forecast model
neovascular AMD
population study
public healthcare
treatment incidences
Journal
Acta ophthalmologica
ISSN: 1755-3768
Titre abrégé: Acta Ophthalmol
Pays: England
ID NLM: 101468102
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
revised:
29
12
2020
received:
15
11
2020
accepted:
02
02
2021
pubmed:
19
2
2021
medline:
28
1
2022
entrez:
18
2
2021
Statut:
ppublish
Résumé
The number of patients receiving anti-VEGF therapy has increased rapidly since its introduction in Denmark in 2007, placing an enormous pressure on the public healthcare system. In this study, we attempt to describe this growth and identify the factors driving it. Data on treatment of the entire population of neovascular AMD patients in the Capital Region of Denmark between 2007 and 2019 was retrieved. The age and sex standardized incidences of first time treatment and changes in duration of treatment were analysed. The number of patients in active treatment increased from 576 in 2007 to 3684 in 2019. The growth was initially driven by accumulation of patients continuing anti-VEGF therapy for extended periods of time (259 patients/year). As larger numbers of patients began to be discharged, the increase slowed to 181 patients/year in late 2010s, with demographic change becoming the main growth driving factor. The incidence of first treatment increased slightly during the study period, mainly for individuals over 85 years. For patients under 85 years, treatment incidences closely followed neovascular AMD incidences from population studies. The likelihood of remaining in anti-VEGF treatment after the initial injection followed exponential decay curve (t Treatment incidences and modelling reported in this study might facilitate a more informed and accurate planning of future ophthalmology services.
Substances chimiques
Angiogenesis Inhibitors
0
Vascular Endothelial Growth Factor A
0
Ranibizumab
ZL1R02VT79
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1348-e1353Informations de copyright
© 2021 Acta Ophthalmologica Scandinavica Foundation. Published by John Wiley & Sons Ltd.
Références
Baek SK, Kim JH, Kim JW & Kim CG (2019): Increase in the population of patients with neovascular age-related macular degeneration who underwent long-term active treatment. Sci Rep 9: 13264.
Bloch SB (2013): Implementation studies of ranibizumab for neovascular age-related macular degeneration. PhD Thesis. University of Copenhagen. https://doi.org/10.1111/aos.12272.
Danish Statistical Office 2020, viewed 23rd August 2020, https://www.dst.dk/da/Statistik/statistikbanken#.
Demir E, Southern D, Verner A & Amoaku W (2018): A simulation tool for better management of retinal services. BMC Health Serv Res 18: 759.
Karagiannis DA, Lygerou M, Papadopoulos G et al. (2020): A multicenter, cross-sectional study of the incidence of major macular diseases that cause visual impairment and require therapeutic intervention in Greece: The advice study. Clin Ophthalmol 14: 1417-1426.
Khanna S, Komati R, Eichenbaum DA, Hariprasad I, Ciulla TA & Hariprasad SM (2019): Current and upcoming anti-VEGF therapies and dosing strategies for the treatment of neovascular AMD: a comparative review. BMJ Open Ophthalmol 4(1): e000398.
Li JQ, Welchowski T, Schmid M, Mauschitz MM, Holz FG & Finger RP (2019): Prevalence and incidence of age-related macular degeneration in Europe: A systematic review and meta-analysis. Br J Ophthalmol 104: 1077-1084.
Owen CG, Jarrar Z, Wormald R, Cook DG, Fletcher AE & Rudnicka AR (2012): The estimated prevalence and incidence of late stage age related macular degeneration in the UK. Br J Ophthalmol 96: 752-756.
Parvin P, Zola M, Dirani A, Ambresin A & Mantel I (2017): Two-year outcome of an observe-and-plan regimen for neovascular age-related macular degeneration treated with Aflibercept. Graefes Arch Clin Exp Ophthalmol 255: 2127-2134.
Rudnicka AR, Kapetanakis VV, Jarrar Z, Wathern AK, Wormald R, Fletcher AE, Cook DG & Owen CG (2015): Incidence of late-stage age-related macular degeneration in American whites: Systematic review and meta-analysis. Am J Ophthalmol 160: 85-93.e3.
Sedeh FB, Scott DAR, Subhi Y & Sørensen TL (2017): Prevalence of neovascular age-related macular degeneration and geographic atrophy in Denmark. Dan Med J 64: A5422.
Subhi Y & Sørensen TL. (2017): Neovascular age-related macular degeneration in the very old (≥90 years): epidemiology, adherence to treatment, and comparison of efficacy. J Ophthalmol 2017: 1-9.
Wong WL, Su X, Li X, Cheung CMG, Klein R, Cheng C-Y & Wong TY (2014): Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Heal 2: e106-e116.